IGM Biosciences Stock: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points
Warut Lakam/Moment via Getty Images IGM Biosciences, Inc. (NASDAQ:IGMS) has a strong pipeline of clinical candidates, including imvotamab, a CD20 ...
Tag: Imvotamab
The latest news and updates about the AI Technology and Latest Tech Updates around the world... PouroverAI keeps you in the loop.